Akshat Jain: Reassessing Cost-Effectiveness of Iron Deficiency Anemia Treatments
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about his recent article published in Blood Advances:
”Happy to share our New Publication in Blood Advances.
We address an important question in the management of iron deficiency anemia (IDA) and the interpretation of health economics bringing global burden of this significant health morbidity per World Health Organization.
While recent modeling suggested that first-line intravenous (IV) iron may be the most cost-effective strategy for women with heavy menstrual bleeding, our publication emphasizes that cost-effectiveness is only as strong as the assumptions and comparators included in the model and real world avalaibility of these treatment options.
Key scientific messages from this publication:
- Calls for cautious interpretation of cost-effectiveness models that rely on uncertain assumptions regarding adherence, quality-of-life estimates, and long-term outcomes.
- Highlights the omission of ferric carboxymaltose (FCM)—one of the most widely used contemporary IV iron formulations—which may substantially influence both healthcare costs, new risks of bone health and patient outcomes.
- Brings a global health perspective to the discussion, recognizing that in many low- and middle-income countries, oral iron remains the only practical and affordable treatment option because of resource and infrastructure limitations.
- Encourages future comparative economic studies that include contemporary IV iron formulations while accounting for regional healthcare realities before translating modeling results into universal clinical policy.
Scientific progress depends not only on new discoveries but also on thoughtful evaluation of the evidence that guides patient care.
As healthcare systems increasingly rely on economic modeling to shape policy, ensuring that these analyses are comprehensive, globally relevant, and clinically applicable is essential.
Proud to contribute to this important discussion in hematology and healtheconomics.”
Title: Iron Deficiency: Cost-Effectiveness and Global Applicability
Authors: Akshat Jain
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 17, 2026, 20:38Konstantinos Bistas: Reduced Circulating Tregs in Pediatric Chronic Neutropenia
-
Sep 17, 2026, 15:33Gopal Patidar: Honoured to Contribute to the ASFA 2026 Guidelines for Therapeutic Apheresis
-
Sep 17, 2026, 20:36Cosima C. Hoch: Developing a 3D Organotypic Co-Culture Model for Pleomorphic Adenoma
-
Sep 17, 2026, 20:19Riten Kumar: Boston Children’s Hospital Ranked No. 1 in Seven Pediatric Specialties
-
Sep 17, 2026, 20:17Katrina Snow: Whole Blood or Component Therapy – Which Would You Choose?
-
Sep 17, 2026, 16:30Daria Camilli: Empowering Bleeding Disorder Advocacy Through Health Economics
-
Sep 17, 2026, 16:17Mehran Ghasemzadeh: Platelet NK Cell Crosstalk in Advanced Coronary Artery Disease
-
Sep 17, 2026, 16:16Barbara Adams Krolak: Do GLP-1s Affect Blood Clot Risk?
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management